CRISPR/Cas13a-assisted rapid and portable HBV DNA detection for low-level viremia patients

BACKGROUND & AIMS: The WHO declared to eliminate hepatitis B virus (HBV) by 2030. However, an increasing number of patients are presenting with low-level viremia (LLV) with the widespread use of antiviral medications. The diagnostic efficiency and coverage area of HBV infection are low. Hence, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Yuan, Fan, Zihao, Xu, Ling, Cao, Yaling, Chen, Sisi, Pan, Zhenzhen, Gao, Yao, Li, Hao, Zheng, Sujun, Ma, Yingmin, Duan, Zhongping, Zhang, Xiangying, Ren, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Hepatitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946317/
https://www.ncbi.nlm.nih.gov/pubmed/36735916
http://dx.doi.org/10.1080/22221751.2023.2177088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946317/
https://www.ncbi.nlm.nih.gov/pubmed/36735916
http://dx.doi.org/10.1080/22221751.2023.2177088

Ejemplares similares